Analysis on the interaction and binding properties of daphnoretin and human serum albumin in the presence of cisplatin: multi-spectroscopic methods and docking simulation

Liang, Yuanhao; Xu, Liang; Yang, Hongtian; Xu, Wenli; Hu, Ruixue; Fan, Xiaoying; Liu, Yufeng

doi:10.1016/j.ejps.2021.105723

Cited by 19 publications

(6 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Albumin delivers platinum agents e ciently to tumor tissue via these complexes. Albumin also protects against platinumassociated toxicities by reducing the levels of albumin-free platinum agents that induce cytotoxicity [12][13][14]. In addition, albumin is known to have immunomodulatory functions in tumor microenvironments.…”

Section: Discussionmentioning

confidence: 99%

“…For example, fat tissue-associated factors, such as leptin, fatty acids, and pro-in ammatory cytokines, contribute to cancer immunity [11]. In addition, serum albumin binds to chemotherapeutic agents and delivers them to tumor tissues [12][13][14]. The clinical bene ts of cancer therapy are achieved through both effective anti-cancer therapy and preservation of the host status.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy

Karayama

Inoue

Yasui

et al. 2021

Preprint

View full text Add to dashboard Cite

Background The nutritional status can potentially affect the efficacy of cancer therapy. We evaluated the relationships between the nutritional status and the efficacy of chemotherapy in patients with non-small-cell lung cancer (NSCLC). Methods The Geriatric Nutritional Risk Index (GNRI), calculated from body weight and serum albumin, was retrospectively evaluated in 148 patients with NSCLC who received first-line platinum-based chemotherapy and scored as low or high. Results Patients with a high GNRI had a significantly higher overall response rate (ORR; 61.8% [95% confidence interval {CI} = 52.5–70.3%] vs. 34.2% [95% CI = 21.2–50.1%, p < 0.004), longer median progression-free survival (PFS; 6.3 months [95% CI = 5.6–7.2 months] vs. 3.8 months [95% CI = 2.5–4.7 months], p < 0.001), and longer median overall survival (OS; 22.8 months [95% CI = 16.7–27.2 months] vs. 8.5 months [95% CI = 5.4–16.0 months], p < 0.001) than those with low GNRI. High GNRI was independently predictive of longer PFS and OS, but not ORR, in multivariate Cox proportional hazard analyses. In 71 patients who received second-line non-platinum chemotherapy, patients with high GNRI exhibited significantly longer PFS and OS than those with low GNRI (both p < 0.001). Conclusions GNRI was predictive of prolonged survival in patients with NSCLC who received first-line platinum-based chemotherapy and second-line non-platinum chemotherapy. Assessment of the nutritional status may be useful for predicting the efficacy of chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy

Karayama

Inoue

Yasui

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Albumin delivers platinum agents efficiently to tumor tissue via these complexes. Albumin also protects against platinum-associated toxicities by reducing the levels of albumin-free platinum agents that induce cytotoxicity [ 12 – 14 ]. In addition, albumin is known to have immunomodulatory functions in tumor microenvironments.…”

Section: Discussionmentioning

confidence: 99%

“…For example, fat tissue-associated factors, such as leptin, fatty acids, and pro-inflammatory cytokines, contribute to cancer immunity [ 11 ]. In addition, serum albumin binds to chemotherapeutic agents and delivers them to tumor tissues [ 12 – 14 ]. The clinical benefits of cancer therapy are achieved through both effective anti-cancer therapy and preservation of the host status.…”

Section: Introductionmentioning

confidence: 99%

Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy

et al. 2021

View full text Add to dashboard Cite

Background The nutritional status can potentially affect the efficacy of cancer therapy. The Geriatric Nutritional Risk Index (GNRI), a simple index for evaluating nutritional status calculated from body weight and serum albumin levels, has been reported to be associated with the prognosis of various diseases. However, the relationships between GNRI and the efficacy of platinum-based chemotherapy in patients with non-small-cell lung cancer (NSCLC) are unknown. Methods The pretreatment levels of GNRI were retrospectively evaluated in 148 chemo-naïve patients with advanced NSCLC who received first-line platinum-based chemotherapy and scored as low or high. Results Patients with a high GNRI had a significantly higher overall response rate (ORR; 44.5% [95% confidence interval {CI} = 35.6%–53.9%] vs. 15.8% [95% CI = 7.4%–30.4%, p = 0.002), longer median progression-free survival (PFS; 6.3 months [95% CI = 5.6–7.2 months] vs. 3.8 months [95% CI = 2.5–4.7 months], p < 0.001), and longer median overall survival (OS; 22.8 months [95% CI = 16.7–27.2 months] vs. 8.5 months [95% CI = 5.4–16.0 months], p < 0.001) than those with low GNRI. High GNRI was independently predictive of better ORR in multivariate logistic regression analysis and longer PFS and OS in multivariate Cox proportional hazard analyses. In 71 patients who received second-line non-platinum chemotherapy, patients with high GNRI exhibited significantly longer PFS and OS than those with low GNRI (both p < 0.001). Conclusions GNRI was predictive of prolonged survival in patients with NSCLC who received first-line platinum-based chemotherapy and second-line non-platinum chemotherapy. Assessment of the nutritional status may be useful for predicting the efficacy of chemotherapy.

show abstract

“…DAP, a dicoumarin derivative, could inhibit various cancer cell growth, especially inducing HCC apoptosis via an increase in Bax and p53 expression and a decrease in Bcl2 expression (Yu et al, 2019;Badawy et al, 2021;Wang et al, 2021;Yao et al, 2021). However, DAP exhibited low water solubility and rapid clearance from the bloodstream, thus resulting in a short T1/2 in the plasma (3.5 h) (Hu et al, 2017;Liang et al, 2021). Therefore, it is imperative to develop a more effective therapeutic strategy to overcome the limitation of DAP in the treatment of HCC.…”

Section: Introductionmentioning

confidence: 99%

A nano-preparation approach to enable the delivery of daphnoretin to potentiate the therapeutical efficacy in hepatocellular cancer

Zhu

Wang²,

Feng³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Daphnoretin (DAP), isolated from a traditional Chinese medicine Wikstroemia indica (Linn. C. A. Meyer), could induce apoptosis of hepatocellular cancer (HCC) and inhibit tumor growth. However, the application of DAP in cancer therapies was hampered because to its poor solubility. Herein, this study aimed to design an approach of double-targeted nano-preparation to enable the delivery of DAP to potentiate the therapeutical efficacy in liver cancer via glycyrrhetinic acid-polyethylene glycol-block-poly (D,L-lactic acid)/polyethylene glycol-block-poly (D,L-lactic acid)-DAP (GPP/PP-DAP). In particular, the purity of separated DAP was up to 98.12% for preparation research. GPP/PP-DAP was successfully prepared by the thin-film hydration method. Subsequently, the GPP/PP-DAP was optimized by univariate analysis and the response surface methodology, producing a stable and systemically injectable nano-preparation. Impressively, on the one hand, cytotoxicity studies showed that the IC50 of the GPP/PP-DAP was lower than that of free DAP. On the other hand, the GPP/PP-DAP was more likely to be endocytosed by HepG2 cells and targeted to the liver with orthotopic tumors, potentiating the therapeutical efficacy in HCC. Collectively, both in vitro and in vivo results indicated the excellent tumor inhibition and liver targeting of GPP/PP-DAP, suggesting the nano-preparation could serve as a potential drug delivery system for natural ingredients with anti-hepatoma activity to lay the theoretical foundation for clinical application.

show abstract

Analysis on the interaction and binding properties of daphnoretin and human serum albumin in the presence of cisplatin: multi-spectroscopic methods and docking simulation

Cited by 19 publications

References 51 publications

Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy

Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy

Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy

A nano-preparation approach to enable the delivery of daphnoretin to potentiate the therapeutical efficacy in hepatocellular cancer

Contact Info

Product

Resources

About